We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept

December 16, 2020

Neuraxpharm announces closing of its acquisition by a company backed by funds advised by Permira.

Neuraxpharm announces that its acquisition by a company backed by funds advised by global private equity firm, Permira, and previously announced on 22 September 2020, has now been closed.

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: “As we look ahead to the next chapter in Neuraxpharm’s development, the management team would like to thank Apax Partners for its support and confidence in our business over the last four years. A strong geographical expansion and a significant investment in our product pipeline have allowed to create a pan-European platform to support rapid and sustainable growth. We are now delighted to be supported by Permira, a strongly established growth investor, as we continue our journey to further grow and strengthen our position as a leading CNS specialist.”